The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...

BRIDGEWATER, N.J., March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...

Alnylam’s second showing on this list is for its Sanofi-partnered siRNA therapy fitusiran, which the companies proposed for the treatment of hemophilia A and B. The FDA’s verdict is expected on March ...

As Microsoft Word and PowerPoint continually improve their feature sets, the two apps are slowly strangling one of Microsoft’s traditional Office apps: Microsoft Publisher. Microsoft now says ...